Contact lens maker Safigel was acquired by Bruno Pharmaceuticals S.P.A., a privately held, family owned, Italian pharmaceutical company based in Rome.
Chicago-Contact lens maker Safigel announced that the company was recently acquired by Bruno Pharmaceuticals S.P.A., a privately held, family owned, Italian pharmaceutical company based in Rome.
According to Safigel, Bruno shares a kindred synergy with Safigel’s mission, “to provide new, groundbreaking alternatives to eye-care professionals (ECPs) who fit patients with contact lenses, and to stay on the cutting-edge of bringing major technological innovations to the eye-care marketplace that benefit contact lens wearers.”
According to Vincenzo Bruno, Italian Chief Executive Officer, the two companies will “offer even more” to U.S. ECPs in the coming months.
Although details of the transaction were not disclosed, Safigel said in a statement that it will now expand its sales and marketing efforts on its sodium hyaluronate contact lens, which has seen steady growth.
For more articles in this issue of InDispensable, click here.